Author/Authors :
Rha، نويسنده , , Seung-Woon and Kuchulakanti، نويسنده , , Pramod K. and Pakala، نويسنده , , Rajbabu and Cheneau، نويسنده , , Edouard and Fournadjiev، نويسنده , , Jana A. and Pinnow، نويسنده , , Ellen and GebreEyesus، نويسنده , , Afework and Aggrey، نويسنده , , George and Wang، نويسنده , , Zuyue and Pichard، نويسنده , , Augusto D. and Satler، نويسنده , , Lowell F. and Kent، نويسنده , , Kenneth M. ، نويسنده ,
Abstract :
Bivalirudin (Angiomax) is increasingly used as a substitute for heparin in a variety of percutaneous coronary interventions. This retrospective, observational study aimed to evaluate the efficacy and safety of bivalirudin compared with heparin as an antithrombotic regimen in patients treated with sirolimus-eluting stents (Cypher) and found that bivalirudin is clinically safe and feasible, with fewer vascular and ischemic complications compared with heparin.
